Actively Recruiting
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
Led by Centre Oscar Lambret · Updated on 2026-03-18
100
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
Sponsors
C
Centre Oscar Lambret
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
CONDITIONS
Official Title
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or more
- Histologically confirmed breast cancer at any stage
- Requiring surgery or tumor biopsy as standard of care
- Any or no systemic treatment
- Signed informed consent
- Health insurance coverage
You will not qualify if you...
- Opposed to biospecimen collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oscar Lambret Center
Lille, France, 59000
Actively Recruiting
Research Team
N
Nawale HAJJAJI, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here